Business Context and Reporting Period
This Form 8-K Current Report, dated January 29, 2015, is filed by Platform Specialty Products Corporation (Platform). The filing details the entry into a Material Definitive Agreement regarding a debt offering intended to finance the proposed acquisition of Arysta LifeScience Limited (the "Arysta Acquisition"). The offering closed on February 2, 2015.
Key Financial Metrics and Debt Structure
The filing discloses the issuance of senior notes with the following terms:
- Additional USD Notes: $100 million aggregate principal amount of 6.500% senior notes due 2022, issued at $1,010 per $1,000 principal amount.
- Initial USD Notes: $1.00 billion aggregate principal amount of 6.500% senior notes due 2022.
- EUR Notes: €350 million aggregate principal amount of 6.000% senior notes due 2023.
- Total Notes Issued: The Additional USD Notes are fungible with the Initial USD Notes, creating a single series of USD Notes.
- Interest Payments: Payable semi-annually in arrears on February 1 and August 1, commencing August 1, 2015.
- Escrow Arrangement: Gross proceeds from the Additional USD Notes were deposited into an escrow account pending the closing of the Arysta Acquisition.
The filing does not provide specific revenue, profit, cash flow, or liquidity metrics for the reporting period, as this is a transactional filing rather than a periodic financial report.
Material Changes and Transaction Details
The primary material change is the expansion of the company's debt capital structure to fund the Arysta Acquisition. Key transactional details include:
- Acquisition Financing: The notes were issued to fund the acquisition of Arysta LifeScience Limited, expected to close in the first quarter of 2015.
- Merger Structure: Upon closing the acquisition, the Escrow Issuer will merge into Platform, and Platform will assume the obligations of the Notes.
- Guarantees: Following the merger, the Notes will be unconditionally guaranteed on a senior unsecured basis by Platform's guarantors.
- Ranking: The Notes will rank equally with existing senior unsecured debt and will be effectively subordinated to secured indebtedness.
Outlook, Risks, and Contingencies
Contingent Redemption: If the Arysta Acquisition does not close by August 17, 2015, the Indenture requires a mandatory redemption of all outstanding Notes at 100% of principal plus accrued interest.
Risks and Covenants:
- Acquisition Risk: There is no assurance that the Arysta Acquisition will be consummated or that the Merger will take place.
- Covenants: The Indenture limits the ability to incur additional indebtedness, pay dividends, repurchase stock, make loans, sell assets, or enter into affiliate transactions.
- Events of Default: Includes failure to pay principal or interest, breach of covenants, bankruptcy events, and failure to comply with escrow agreements.
- Change of Control: Triggers an offer to purchase all Notes at 101% of principal plus accrued interest.
Investor Verification Checklist
- Verify the closing status of the Arysta LifeScience Limited acquisition to determine if the mandatory redemption clause (August 17, 2015 deadline) is triggered.
- Confirm the release of escrowed funds to Platform upon the consummation of the acquisition.
- Review the full text of the Indenture (Exhibit 4.1) for specific definitions of permitted asset sales and debt incurrence limits.
- Assess the impact of the new debt load on the company's leverage ratios and interest coverage post-acquisition.
- Monitor the status of the merger between the Escrow Issuer and Platform to confirm the assumption of debt obligations.